Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 116 participants.
Also called NCT02933788
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 116 participants
- Registry
-
NCT02933788
-
- Other papers using this trial's data
- Comparative Study of Ex Vivo Antiplatelet Activity of Aspirin and Cilostazol in Patients with Diabetes and High Risk of Cardiovascular Disease
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Unknown status
Technical summary
Registry record NCT02933788. Randomized; no masking; primary purpose prevention. Start 2016-10 (registry gives no type); primary completion 2016-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Cilostazol
- Intervention (Drug)
- Acetylsalicylic acid
- Lead sponsor
- Kangbuk Samsung Hospital
- Collaborator
- Asan Medical Center
Record details
- Record id
cardio:ct-nct02933788- Content hash
2d293340af9a211dc1f5aa3d97d57a7b042b1b61719fde4cfd7e5c6774a63d4d